Positive baxdrostat Phase III trial in uncontrolled hypertension
UK pharma major AstraZeneca (LSE: AZN) today announced positive high-level results from the baxdrostat BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension.
These data showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically-significant and clinically-meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks, marking a potential turning point in how we approach one of the most persistent global health challenges. The trial also successfully met all secondary endpoints. Patients with uncontrolled or treatment resistant hypertension received baxdrostat or placebo on top of standard of care.
AstraZeneca, whose shares edged up almost 2% to 10,762 pence on the news, acquired rights to baxdrostat along with its $1.8 billion buy of USA-based clinical stage biotech CinCor Pharma in 2023.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze